Terms: = Sarcomas AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
813 results:
1. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
[TBL] [Abstract] [Full Text] [Related]
2. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
[TBL] [Abstract] [Full Text] [Related]
3. Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours.
Zago Baltazar R; Claerhout S; Vander Borght S; Spans L; Sciot R; Schöffski P; Hompes D; Sinnaeve F; Wafa H; Renard M; van den Hout MF; Vernemmen A; Libbrecht L; De Roo AK; Mazzeo F; van Marcke C; Deraedt K; Bourgain C; Vanden Bempt I
J Pathol Clin Res; 2024 May; 10(3):e12376. PubMed ID: 38738521
[TBL] [Abstract] [Full Text] [Related]
4. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
[TBL] [Abstract] [Full Text] [Related]
5. Large-vessel vasculitis possibly induced by braf and MEK inhibitors for braf V600E positive lung adenocarcinoma.
Ichikawa K; Ohno S; Kubo S; Nakajima H
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719253
[TBL] [Abstract] [Full Text] [Related]
6. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
7. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract] [Full Text] [Related]
8. Temporal trends and regional variability in braf and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
9. Tumor-targeted therapy with braf-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract] [Full Text] [Related]
10. braf V600E Mutation in Malignant Melanoma-A Romanian Research Experience.
Avădănei ER; Căruntu ID; Nucă I; Balan R; Lozneanu L; Giusca SE; Amalinei C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541077
[No Abstract] [Full Text] [Related]
11. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract] [Full Text] [Related]
12. Identification of Germline
Pires C; Saramago A; Moura MM; Li J; Donato S; Marques IJ; Belo H; Machado AC; Cabrera R; Grünewald TGP; Leite V; Cavaco BM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396644
[TBL] [Abstract] [Full Text] [Related]
13. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
[TBL] [Abstract] [Full Text] [Related]
14. CD30 expression in an emerging group of mesenchymal spindle cell neoplasms with ALK fusion detected by flow cytometry and immunohistochemistry.
Iwakoshi A; Kikui H; Nakashima R; Goto Y; Ichikawa D; Sasaki E; Sekimizu M; Hattori H; Maeda N
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23228. PubMed ID: 38380728
[TBL] [Abstract] [Full Text] [Related]
15. Clinical features and mutation analysis of class 1/2/3 braf mutation colorectal cancer.
Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
[TBL] [Abstract] [Full Text] [Related]
16. Is there a prognostic difference among stage I lung adenocarcinoma patients with different braf-mutation status?
Ma SS; Wang RR; Peng Q; Liu Y; Qian JY; Li MJ; Li K; Huang ZY; Wu LL; Xie D
Thorac Cancer; 2024 Mar; 15(9):715-721. PubMed ID: 38362771
[TBL] [Abstract] [Full Text] [Related]
17. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations.
Klubíčková N; Dermawan JK; Mosaieby E; Martínek P; Vaněček T; Hájková V; Ptáková N; Grossmann P; Šteiner P; Švajdler M; Kinkor Z; Michalová K; Szepe P; Plank L; Hederová S; Kolenová A; Spasov NJ; Kosemehmetoglu K; Pažanin L; Špůrková Z; Baník M; Baumruk L; Meyer A; Kalmykova A; Koshyk O; Michal M; Michal M
J Pathol; 2024 May; 263(1):61-73. PubMed ID: 38332737
[TBL] [Abstract] [Full Text] [Related]
19. [Progress of braf Gene Alteration in Non-small Cell Lung Cancer].
Deng L; Yang Y; Huang J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
[TBL] [Abstract] [Full Text] [Related]
20. Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A.
Huang D; Wu Z; Wu Z; Li N; Hao L; Li K; Zeng J; Qiu B; Zhang S; Yan J
Mol Cancer Ther; 2024 May; 23(5):721-732. PubMed ID: 38295302
[TBL] [Abstract] [Full Text] [Related]
[Next]
